已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

阿替唑单抗 医学 肿瘤科 内科学 临床终点 多西紫杉醇 转移性尿路上皮癌 人口 化疗 催眠药 性能状态 随机对照试验 癌症 免疫疗法 彭布罗利珠单抗 尿路上皮癌 膀胱癌 环境卫生
作者
Thomas Powles,Ignacio Durán,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Fléchon,Gwénaëlle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui
出处
期刊:The Lancet [Elsevier BV]
卷期号:391 (10122): 748-757 被引量:1281
标识
DOI:10.1016/s0140-6736(17)33297-x
摘要

Background Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy in this patient population. Methods We conducted this multicentre, open-label, phase 3 randomised controlled trial (IMvigor211) at 217 academic medical centres and community oncology practices mainly in Europe, North America, and the Asia-Pacific region. Patients (aged ≥18 years) with metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy were randomly assigned (1:1), via an interactive voice and web response system with a permuted block design (block size of four), to receive atezolizumab 1200 mg or chemotherapy (physician's choice: vinflunine 320 mg/m2, paclitaxel 175 mg/m2, or 75 mg/m2 docetaxel) intravenously every 3 weeks. Randomisation was stratified by PD-L1 expression (expression on <1% [IC0] or 1% to <5% [IC1] of tumour-infiltrating immune cells vs ≥5% of tumour-infiltrating immune cells [IC2/3]), chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of prognostic factors (none vs one, two, or three). Patients and investigators were aware of group allocation. Patients, investigators, and the sponsor were masked to PD-L1 expression status. The primary endpoint of overall survival was tested hierarchically in prespecified populations: IC2/3, followed by IC1/2/3, followed by the intention-to-treat population. This study, which is ongoing but not recruiting participants, is registered with ClinicalTrials.gov, number NCT02302807. Findings Between Jan 13, 2015, and Feb 15, 2016, we randomly assigned 931 patients from 198 sites to receive atezolizumab (n=467) or chemotherapy (n=464). In the IC2/3 population (n=234), overall survival did not differ significantly between patients in the atezolizumab group and those in the chemotherapy group (median 11·1 months [95% CI 8·6–15·5; n=116] vs 10·6 months [8·4–12·2; n=118]; stratified hazard ratio [HR] 0·87, 95% CI 0·63–1·21; p=0·41), thus precluding further formal statistical analysis. Confirmed objective response rates were similar between treatment groups in the IC2/3 population: 26 (23%) of 113 evaluable patients had an objective response in the atezolizumab group compared with 25 (22%) of 116 patients in the chemotherapy group. Duration of response was numerically longer in the atezolizumab group than in the chemotherapy group (median 15·9 months [95% CI 10·4 to not estimable] vs 8·3 months [5·6–13·2]; HR 0·57, 95% CI 0·26–1·26). In the intention-to-treat population, patients receiving atezolizumab had fewer grade 3–4 treatment-related adverse events than did those receiving chemotherapy (91 [20%] of 459 vs 189 [43%] of 443 patients), and fewer adverse events leading to treatment discontinuation (34 [7%] vs 78 [18%] patients). Interpretation Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1 (IC2/3). However, the safety profile for atezolizumab was favourable compared with chemotherapy, Exploratory analysis of the intention-to-treat population showed well-tolerated, durable responses in line with previous phase 2 data for atezolizumab in this setting. Funding F Hoffmann-La Roche, Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蓝色天空完成签到,获得积分10
刚刚
西柚完成签到,获得积分10
3秒前
迷路聋五完成签到 ,获得积分10
3秒前
4秒前
汉堡包应助IMIke采纳,获得10
4秒前
在水一方应助科研通管家采纳,获得10
4秒前
柯一一应助科研通管家采纳,获得10
5秒前
科研通AI5应助科研通管家采纳,获得10
5秒前
丘比特应助科研通管家采纳,获得10
5秒前
科研通AI5应助科研通管家采纳,获得10
5秒前
ding应助科研通管家采纳,获得10
5秒前
柯一一应助科研通管家采纳,获得10
5秒前
FashionBoy应助科研通管家采纳,获得10
5秒前
柯一一应助科研通管家采纳,获得10
5秒前
深情安青应助科研通管家采纳,获得10
5秒前
烟花应助科研通管家采纳,获得10
5秒前
6秒前
TiAmo完成签到,获得积分20
6秒前
几两发布了新的文献求助10
8秒前
相对发布了新的文献求助20
9秒前
曙光森林发布了新的文献求助10
9秒前
10秒前
小包子完成签到,获得积分10
11秒前
12秒前
舒远发布了新的文献求助10
13秒前
13秒前
无辜的秀发布了新的文献求助10
16秒前
MchemG应助TXZ06采纳,获得30
17秒前
咩咩应助Maga采纳,获得10
17秒前
17秒前
18秒前
Lzy发布了新的文献求助10
18秒前
z泽泽完成签到,获得积分10
20秒前
21秒前
崔洪瑞完成签到,获得积分10
22秒前
Vicktor2021发布了新的文献求助10
22秒前
跨越山海的热爱完成签到 ,获得积分10
24秒前
26秒前
26秒前
彩色靖儿发布了新的文献求助10
31秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3959835
求助须知:如何正确求助?哪些是违规求助? 3506093
关于积分的说明 11127809
捐赠科研通 3238043
什么是DOI,文献DOI怎么找? 1789445
邀请新用户注册赠送积分活动 871773
科研通“疑难数据库(出版商)”最低求助积分说明 803021